Vijaya Diagnostic Centre Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong quarter, seasonal tailwinds: Revenue hit a record ~₹205 crores, with Q3 surpassing Q2 despite typical festive softness. Growth was balanced across radiology and pathology, aided by favorable seasonality and pre-festive demand spillover.
• New hubs break even in record time: Two West Bengal hubs launched in Q1 FY26 achieved breakeven within 3 quarters, well ahead of the 1-year timeline, driven by an integrated specialized reporting model that creates a competitive moat.
• Margin expansion held back by reinvestment: EBITDA margin rose 221 bps YoY to 41.9%, but management is holding the official guidance at 40%, choosing to channel faster hub leverage into talent and IT investments rather than letting margins run.
• Expansion is disciplined, not aggressive: FY27 plans call for only 4–5 new hubs and 10–12 spokes, with management prioritizing stabilization of existing assets and citing ground-level operational bandwidth as the real constraint.
• What to watch next quarter: Whether Q4 surpasses the 15% full-year growth guidance as promised, any update on the GLP-1 testing package, and the pace of ramp-up in the four newest hubs.

Quarterly Performance & Drivers

• Record revenue despite seasonality: Q3 revenue of ~₹205 crores was the highest ever, surpassing Q2 even though Q3 normally sees festive softness. Growth was balanced between radiology, driven by hub expansions and brand reception in new geographies, and pathology, driven by the Wellness segment and network expansion.
• Hyderabad delivered standout growth: The core market grew 15% YoY from existing capacity with no new hubs added in the last 2–3 quarters. Favorable pathology season, spillover from an extended monsoon in Q2, and pre-festive demand all contributed, and Vijaya outpaced the industry to gain market share.
• Pune grew on network expansion: The acquired PH asset grew ~8% YoY, primarily from two new hubs that are ramping up as brand visibility builds. Management expects further traction in the coming quarters.
• Wellness is a structural growth driver: Rising health consciousness and more companies offering preventive health checks are creating steady revenue, especially in Tier 2 and Tier 3 geographies where this demand barely existed pre-COVID. Even the smallest spoke can run full master health checkups, so network expansion directly expands the Wellness funnel.
• Realization will stay range-bound: As hubs stabilize, a rising mix of pathology work dilutes average realizations, but annual tariff increases of 1–1.5% offset the hit. Management expects ARPPs to stay within plus or minus 3–4%.

Siva Rama Raju: "In fact, that is one of the reasons, Anshul, why we say health care being seasonal. It is always, I would say, better to look at a full year level rather than seeing quarter-on-quarter."

Hub Economics & The Faster Breakeven Story

• West Bengal hubs broke even in 3 quarters: Two hubs launched in Q1 FY26 (Krishnanagar, Barasat) hit breakeven well ahead of the standard 1-year timeline. Management credits the integrated specialized reporting model and extra effort from local teams, but explicitly declined to declare this replicable across all new geographies.
• The competitive moat is integrated, specialized radiology: Vijaya's radiologists, cardiologists, and nuclear medicine specialists work as one team, and pathology and radiology talk to each other to deliver a final integrated report before the patient leaves. In Rajahmundry, a report that once required a 4-day city trip is now delivered in 4 hours. This model is a key reason for faster breakeven in newer geographies.
• Spoke economics are predictable: Spokes break even within two quarters and turn EBITDA-positive by the third or fourth quarter. At maturity in new regions, a spoke generates ₹1.5–₹2.5 crores in revenue, reaching that level in 18–24 months.
• Bangalore is also ramping well: The Bangalore asset that broke even last quarter continues to ramp, and management plans to concentrate future Karnataka expansion on Bangalore city itself and a few spokes, not on Tier 2/Tier 3 markets in the state.

Suprita Reddy: "If we take Rajahmundry, for example, probably they would have had to come to the city, spend 4 days. We're able to deliver this report in 4 hours sitting in Rajahmundry."

Expansion Strategy & Constraints

• FY27 expansion is measured: The plan calls for 4–5 new hubs and 10–12 spokes, with a focus on stabilizing newly launched hubs, commissioning spokes, investing in technology, and strengthening brand presence in new geographies.
• Operational bandwidth, not capital, is the binding constraint: Management noted a good capex cycle over the last 2–3 years, but said ground-level operational challenges and the need to let existing hubs stabilize before adding more are the real limits on expansion pace.
• No new organic geographies for 2–3 years: Hands are full with current markets, and the priority is deepening presence in existing geographies. The only path into a new geography would be a large, attractively valued M&A opportunity.
• FY28–29 will see the next hub wave: Once the current set of hubs stabilizes, the next set will come, aiming for an optimal mix of spokes and hubs.
• M&A is on the radar but nothing imminent: The company is always looking for a B2C asset in a comfortable geography at a reasonable valuation, but has nothing to share.

Siva Rama Raju: "It is more about, last 2 - 3 years, there's a good capex cycle that we have done... it is more in terms of the ground level operational challenges and also sometimes we have to give the hubs to stabilize before we take on a few more hubs."

Margins & Investment Posture

• EBITDA margin expanded but guidance stays at 40%: Margins rose 221 bps YoY to 41.9%, and PAT margin reached 21%. Despite faster hub breakeven creating center-level operating leverage, management is holding the official EBITDA margin guidance at 40%, citing significant planned investments in talent and IT/digital initiatives to improve customer experience.
• Depreciation should stabilize near-term: The quarterly depreciation run rate is expected to hold steady except for incremental charges from new hubs and spokes in FY27. Under Ind AS 116, the interest portion on leases will decline once the 5-year lease period is crossed, but for the next 1–2 years, depreciation will reflect the current base plus incremental capex.
• Input costs are broadly neutral: Pathology contracts are long-term with volume commitments met and surpassed, so no major changes are foreseen. On the capex side, USD-INR breaching 90 had some negative impact, but the GST rate reduction from 12% to 5% more or less offset it.

Competitive Positioning & Threats

• Disruption and consolidation are distant threats: Management views the much-discussed disruption and consolidation in diagnostics as objects in the side mirror: they appear closer than they really are. The specialized, integrated reporting model and tele-radiology backbone create a moat that pure-play wellness or low-cost competitors cannot easily replicate.
• Tele-radiology creates operating leverage: Specialized doctors across regions deliver high-end reports even in Tier 2 geographies, and PET CTs are ramping quickly in both Tirupati and Vizag because of this differentiated model.
• GLP-1 opportunity is nascent: The company has not seen many inquiries yet, but all required tests are routine and already available. Management plans to have a dedicated package ready in 1–2 months if demand picks up, and may share more by the next earnings call.

Siva Rama Raju: "I think especially in diagnostics, we keep hearing two things. One is the disruption and the consolidation. I think these are like the objects that we see in the side mirror, right. They appear to be closer, but they're very far away."

Guidance & Commitments

Key Metrics